<DOC>
	<DOCNO>NCT01283542</DOCNO>
	<brief_summary>This study assess pasireotide LAR efficacy patient non-functioning pituitary adenoma concern tumor growth .</brief_summary>
	<brief_title>Evaluate Efficacy Safety Pasireotide LAR Treatment Patients With Clinically Non-Functioning Pituitary Adenoma .</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<criteria>Nonfunctioning pituitary adenoma â‰¥ 1cm , patient without previous treatment tumor Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients require surgical intervention relief sign symptom associate tumor compression Previous pituitary surgery Previous medical treatment pituitary tumor Patients receive pituitary irradiation within 10 year prior randomization Prolactin ( PRL ) level &gt; 100 ng/mL . PRL evaluation perform diluted sample make sure avoid `` hook effect . '' Patients present prolactinomas , acromegaly Cushing 's disease Patients compression optic chiasm cause acute clinically significant visual field defect Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Non-functioning pituitary adenoma ,</keyword>
	<keyword>pasireotide LAR ,</keyword>
	<keyword>tumor volume</keyword>
</DOC>